Screening Tests for Coagulation Pathways
The Prothrombin Time (PT/INR) measures the extrinsic and common pathways, the Activated Partial Thromboplastin Time (aPTT) measures the intrinsic and common pathways, and the Thrombin Time (TT) measures the final common pathway (fibrinogen to fibrin conversion). 1
Standard Coagulation Pathway Testing
Extrinsic and Common Pathways: PT/INR
- PT evaluates: Factor VII (extrinsic), plus Factors II, V, X, and fibrinogen (common pathway)
- The PT responds to reductions in three of the four vitamin K-dependent clotting factors (FII, FVII, FX) 2
- Primary clinical use: Monitoring vitamin K antagonists (warfarin), though it has expanded beyond this validated indication 3
Intrinsic and Common Pathways: aPTT
- aPTT evaluates: Factors XII, XI, IX, VIII (intrinsic), plus Factors II, V, X, and fibrinogen (common pathway)
- The aPTT is sensitive to all hemostatic factors except Factor VII 4
- Primary clinical uses: Screening for inherited/acquired factor deficiencies, monitoring unfractionated heparin (though anti-Xa assay is now preferred) 5
Final Common Pathway: Thrombin Time
- TT measures: The conversion of fibrinogen to fibrin by thrombin
- Highly sensitive to direct thrombin inhibitors (dabigatran) and unfractionated heparin 1
- A normal TT can rule out the presence of UFH or dabigatran but cannot quantify their concentration 1
Recommended First-Line Screening Panel
For comprehensive coagulation screening, the 2024 French emergency medicine guidelines recommend measuring PT ratio/INR, aPTT, TT, and anti-Xa activity when anticoagulant status is unknown 1. This combination allows detection of:
- Extrinsic pathway defects: Prolonged PT with normal aPTT (Factor VII deficiency)
- Intrinsic pathway defects: Prolonged aPTT with normal PT (Factors VIII, IX, XI, XII deficiencies—hemophilia)
- Common pathway defects: Both PT and aPTT prolonged (Factors II, V, X, fibrinogen deficiencies)
- Final pathway defects: Prolonged TT with normal PT/aPTT (fibrinogen abnormalities, thrombin inhibitors)
Critical Caveats
Limitations of Standard Tests
- PT and aPTT monitor only the initiation phase of blood coagulation, representing just the first 4% of thrombin production 6
- These tests can appear normal while the overall coagulation state remains abnormal 6
- Important: Using PT and aPTT in concert helps identify specific disorders—hemophilia, liver disease coagulopathy, and disseminated intravascular coagulation 4
Anticoagulant Monitoring Context
- The INR was designed and validated exclusively for monitoring vitamin K antagonists in stable patients 3
- PT/INR lacks validity for general coagulopathy screening, predicting procedural bleeding, or assessing liver disease severity 3
- For direct oral anticoagulants (DOACs), PT and aPTT are variably affected and generally unhelpful—a normal PT or aPTT does NOT exclude DOAC presence 5
Additional Testing Considerations
The 2013 European trauma guidelines recommend routine measurement should include PT, aPTT, fibrinogen, and platelets for detecting post-traumatic coagulopathy 6. Fibrinogen measurement is increasingly emphasized, with 97% of surveyed clinicians including it in first or second-line testing 7.